Antibody response to topical streptokinase

Area of Science:

• Immunology
• Cardiology
• Dermatology

Background:

• Streptokinase is used intravenously for acute myocardial infarction and topically for wounds.
• Antibody response to streptokinase can impact future treatment efficacy.
• Understanding antibody levels after different administration routes is crucial.

Purpose of the Study:

• To compare anti-streptokinase antibody levels after intravenous (IV) vs. topical streptokinase treatment.
• To assess antibody levels in patients with acute myocardial infarction and cutaneous wounds.
• To evaluate the duration of the antibody response to topical streptokinase.

Main Methods:

• Enzyme-linked immunosorbent assay (ELISA) was used to measure anti-streptokinase antibody levels.
• Antibody levels were monitored in three groups: IV streptokinase, topical streptokinase, and a control group.
• Blood samples were collected at baseline, 7 days, 1 month, and 6 months post-treatment.

Main Results:

• Both IV and topical streptokinase induced a significant increase in anti-streptokinase antibodies.
• The antibody response was significantly higher and more sustained in the IV streptokinase group compared to the topical group.
• Anti-streptokinase antibody levels in the topical group returned towards baseline by six months.

Conclusions:

• Topical streptokinase elicits a significant but transient humoral immune response.
• Previous topical streptokinase use may reduce the efficacy of subsequent IV streptokinase treatment.
• Consideration of prior topical streptokinase exposure is recommended for patients requiring IV streptokinase therapy.